Press Releases Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/04/2026 am IST			5-day change	1st Jan Change
133.25 ^USD	+3.77%		+3.38%	-6.05%

14/04	Neurocrine Biosciences Presents Real-World Claims Analysis Demonstrating Greater Treatment Persistence With INGREZZA Capsules Compared To AUSTEDO XR	CI
13/04	Nxera Pharma Co., Ltd. Initiates and Doses First Patient in Phase 2 Trial of Nbi-1117570 for Adults with Schizophrenia	CI

Press Releases

16/04	Neurocrine Biosciences : 2026 Proxy Statement (NBIX 2026 Proxy Statement)	PU
16/04	Neurocrine Biosciences : 2025 Annual Report*	PU
15/04	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results	PR
14/04	Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR	PR
13/04	Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia	AQ
06/04	Neurocrine Biosciences : Presentation (FINAL NBIX SLNO Investor Presentation 0466 Final)	PU
06/04	Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio	PR
26/03	Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings	PR
24/03	Biocom Appoints New Members to Its Board of Directors	AQ
18/03	Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer	PR
11/03	Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum	PR
25/02	Neurocrine Biosciences to Present at Upcoming Investor Conferences in March	PR
12/02	Neurocrine Biosciences : Presentation (Final NBIX Q4 and FY 2025 Earnings Presentation 02 WT5vGfd16)	PU
12/02	Neurocrine Biosciences : Presentation (Final NBIX Q4 and FY 2025 Earnings Presentation 0216)	PU
12/02	Neurocrine: Q4 Earnings Snapshot	AQ
12/02	Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026	PR
26/01	Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia	PR
22/01	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results	PR
16/01	Neurocrine Biosciences Presents Head-to-Head INGREZZA Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR	AQ
15/01	Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR	PR
06/01	Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference	PR
23/12	Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy	PR
17/12	Neurocrine Biosciences : Presentation (NBIX RD Day Presentation 1265)	PU
17/12	Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology	PR
10/12	Neurocrine Biosciences to Host R&D Day on December 16	PR